SELECTED PUBLICATIONS

“The joy of discovery is certainly the liveliest that the mind of man can ever feel”

- Claude Bernard -

 

Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. 35(3):457-472.e5, 2019.

Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O,  Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 25(4):1156-1164, 2019

 

Wang Z., Feng X., Molinolo A.A., Martin D., Vitale-Cross L., Nohata N., Ando M., Wahba A., Amornphimoltham P., Wu X., Gilardi M., Allevato M., Wu V., Steffen D.J., Tofilon P., Sonenberg N., Califano J., Chen Q., Lippman S.M., Gutkind J.S. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. Cancer Res. 2019.

Iglesias-Bartolome R., Uchiyama A., Molinolo A.A., Abusleme L., Brooks S.R., Callejas-Valera J.L., Edwards D., Doci C., Asselin-Labat M.-L., Onaitis M.W., Moutsopoulos N.M., Gutkind* J.S., Morraso* M.I. (*Co-corresponding authors). Transcriptional signature primes human oral mucosa for rapid wound healing. Sci. Transl. Med., 2018, 10, eaap8798

Gutkind J.S., Kostenis E. Arrestins as rheostats of GPCR signaling. Nat. Rev. Mol. Cell Biol., 2018 Jul 19. 10.1038/s41580-018-0041-y

Martin D., Degese M.S., Vitale-Cross L., Iglesias-Bartolome R., Callejas Valera J.L., Wang Z. Feng X., Yeerna H., Vadmal V., Moroishi T., Thorne R., ZaidaM., Siegele B., Cheong S.C., Molinolo A.A., Samuels Y., Tamayo P., Guan K.L., Lippman SM., Lyons J.G., Gutkind J.S. Assembly and Activation of the Hippo Signalome by the FAT1 Tumor Suppressor. Nature Comm., 9:2372, 2018

 

Gutkind JS, Bui JD. The Next Frontier: Head and Neck Cancer Immunoprevention. Cancer Prev Res (AACR) 2:681-683, 2017. PMID29138137

O'Hayre M., Eichel K., Avino S., Zhao X., Steffen D.J., Feng X., Kawakami K., Aoki J., Messer K., Sunahara R., Inoue A., von Zastrow M., and Gutkind J.S. Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK. Science Signaling. 10(484) pii: eaal3395, 2017.

Zhao X., Deng P., Iglesias-Bartolome R., Amornphimoltham P., Steffen D.J., Jin Y., Molinolo A.A., de Castro L.F., Ovejero D., Yuan Q., Chen Q., Han X., Bai D., Taylor S.S., Yang Y., Collins M.T., and Gutkind J.S. Expression of an active Gαs mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. Proc Natl Acad Sci U.S.A. 115:E428-E437, 2017.

William W.N. Jr, Papadimitrakopoulou V., Lee J.J., Mao L., Cohen E.E., Lin H.Y., Gillenwater A.M., Martin J.W., Lingen M.W., Boyle J.O., Shin D.M., Vigneswaran N., Shinn N., Heymach J.V., Wistuba I.I., Tang X., Kim E.S., Saintigny P., Blair E.A., Meiller T., Gutkind J.S., Myers J., El-Naggar A., and Lippman S.M. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol., 2:209-216, 2016.

 

Yamaguchi K., Iglesias-Bartolomé R., Wang Z., Callejas-Valera J.L., Amornphimoltham P., Molinolo A.A., Cohen E.E., Califano J.A., Lippman S.M., Luo J., and Gutkind J.S. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget, 7:10696-10709, 2016.

Doçi C.L., Mikelis C.M., Lionakis M.S., Molinolo A.A., and Gutkind J.S. Genetic identification of SEMA3F as an anti-lymphangiogenic metastasis suppressor gene in head and neck squamous carcinoma. Cancer Research, 75: 2937-2948, 2015.

Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Cancer Prevention Res., 8:197-207, 2015. PMID25681087

Iglesias-Bartolome R, Torres D, Marone R, Feng X, Martin D, Simaan M, Chen M, Weinstein LS, Taylor SS, Molinolo AA, Gutkind JS. Inactivation of a Gαs-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. Nature Cell Biol., 17:793-803, 2015 

Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, Masedunskas A, Weigert R, Chavakis T, Adams R, Offermanns S, Mochizuki N, Zheng Y, Gutkind JS. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nature Commun, 6:6725, 2015.

Yu G.T., Bu L.L., Huang C.F., Zhang W.F., Chen W.J., Gutkind J.S., Kulkarni A.B., Sun Z.J. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget, 6:42067-42080, 2015.

Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind J.S. mTOR inhibition overcomes cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J. Natl. Cancer Inst., 106(9), 2014.  

Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino M, Sodhi A, Chen Q, Gutkind JS. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. Cancer Cell, 25:831-845, 2014. 

O’Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel T, Seshagiri S, Gutkind JS. The emerging mutational landscape of G-proteins and G-protein-coupled receptors in cancer. (Analysis) Nature Reviews Cancer 13(6):412-424, 2013. 

Iglesias-Bartolome R., Martin D.,and Gutkind J.S. Exploiting the head and neck cancer oncogenome: Widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discovery, 3:722-725, 2013.

Vaqué JP, Dorsam RT, Feng X, Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A, Seeger MA, Ksander BR, Teramoto H, Gutkind JS. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing GPCR-initiated mitogenic signals. Molecular Cell, 49:94-108, 2013. 

 

Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, Gutkind JS.  mTOR inhibition protects from epithelial stem cell senescence and radiation-induced mucositis. Cell Stem Cell, 11:401-414, 2012. 

Molinolo A.A., Marsh C., El Dinali M., Gangane N., Jennison K., Hewitt S., Patel V.,  Seiwert T.Y., and Gutkind J.S.. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clinical Cancer Research, 18:2558-2568, 2012.

 

Vitale-Cross L., Molinolo A.A., Martin D., Younis R.H., Maruyama T., Patel P., Chen W., Schneider A., and Gutkind J.S.. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prevention Research, 5:562-573, 2012.

Yagi H., Tan W., Dillenburg-Pilla P., Armando S., Amornphimoltham P., Simaan M., Weigert R., Molinolo A.A., Bouvier M., and Gutkind J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Science Signaling, 4:ra60, 2011. 

Patel V., Marsh C.A., Dorsam R.T., Masedunskas A., Amornphimoltham P., Nathan C.O., Singh B., Weigert R., Molinolo A.A., and Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.  Cancer Research, 71:7103-7112, 2011.

Martin D, Galisteo R, Molinolo AA, Wetzker R, Hirsch E, Gutkind JS.  PI3Kγ mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell, 19: 805-813, 2011.

 

Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prevention Research, 2:27-36, 2009

Castilho R.M, Squarize C.H., Chodosh L.A., Williams B.O., and Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell, 5:279-289, 2009. 

Amornphimoltham P.,Patel V., Leelahavanichkul K., Abraham R.T., and Gutkind J.S. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. Cancer Research, 68:1144-1153, 2008.

Molinolo AA, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. Clinical Cancer Research, 13:4964-4973, 2007.

Basile J.R., Castilho R.M., Williams V.P., and Gutkind JS. Semaphorin4D provides a link between anon guidance processes and tumor-induced angiogenesis, PNAS, 103:9017-9022, 2006. 

Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. Cancer Cell, 10:133-143, 2006.

Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS. mTOR, a molecular target in squamous cell carcinomas of the head and neck. Cancer Research, 65:9953-9961, 2005.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin-β-catenin signaling axis. Science, 310:1504-1510, 2005

Sodhi A, Montaner S, Patel V, Román JG, Li Y, Sausville EA, Sawai ET, Gutkind JS. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A., 101:4821-4826, 2004.

 

Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell, 3:23-36, 2003.

Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nature Cell Biol., 3:580-586, 2001.

Leethanakul C., Patel V., Gillespie J., Pallante M., Ensley J.F., Liotta L.A., Emmert-Buck M., and Gutkind J.S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene, 19:3220-3224, 2000.

Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature, 385:169-172, 1997.

Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S.*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase g. Science, 275:394-397, 1997.

Coso O, Chiariello M, Yu J-C, Crespo P, Teramoto H, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. Cell, 81:1137-1148, 1995.

Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-proteinβγ subunits.  Nature, 369:418-420, 1994.

3855 Health Sciences Drive | Room 2345 | La Jolla | California | 92093-0803

© 2016 by GUTKIND LAB UCSD. All right reserved

Created by Walt Amornphimoltham